Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer.
Humans
Middle Aged
Carcinoma, Non-Small-Cell Lung
/ pathology
Lung Neoplasms
/ pathology
Retrospective Studies
East Asian People
Antineoplastic Agents
/ therapeutic use
Anaplastic Lymphoma Kinase
Lactams, Macrocyclic
/ therapeutic use
Protein-Tyrosine Kinases
Protein Kinase Inhibitors
/ therapeutic use
Japan
anaplastic lymphoma kinase
carcinoma
lorlatinib
non-small-cell lung cancer
real-world clinical trials
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
revised:
16
02
2023
received:
28
07
2022
accepted:
24
02
2023
medline:
5
6
2023
pubmed:
4
3
2023
entrez:
3
3
2023
Statut:
ppublish
Résumé
Alectinib, an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), is the recommended first-line treatment for ALK-positive non-small-cell lung cancer (NSCLC) in Japan. Lorlatinib was approved as a subsequent therapeutic option after progression while receiving ALK TKI treatment. However, data on the use of lorlatinib in the second- or third-line setting after alectinib failure are limited in Japanese patients. This retrospective real-world observational study investigated the clinical effectiveness of lorlatinib in second- or later-line settings after alectinib failure in Japanese patients. Clinical and demographic data collected in the Japan Medical Data Vision (MDV) database between December 2015 and March 2021 were used. Patients diagnosed with lung cancer who received lorlatinib following alectinib failure after the November 2018 marketing approval of lorlatinib in Japan were included. Of 1954 patients treated with alectinib, 221 were identified from the MDV database as receiving lorlatinib after November 2018. The median age of these patients was 62 years. Second-line lorlatinib treatment was reported for 154 patients (70%); third- or later-line lorlatinib treatment was reported for 67 patients (30%). The median duration of treatment (DOT) for all lorlatinib-treated patients was 161 days (95% confidence interval [CI], 126-248), and 83 patients (37.6%) continued treatment after data cut-off (March 31, 2021). Median DOTs of 147 days (95% CI, 113-242) and 244 days (95% CI, 109 to not reached) were reported with second-line and third- or later-line treatment, respectively. Consistent with clinical trial data, this real-world observational study supports data suggesting the effectiveness of lorlatinib after alectinib failure in Japanese patients.
Identifiants
pubmed: 36866958
doi: 10.1111/cas.15777
pmc: PMC10236600
doi:
Substances chimiques
lorlatinib
OSP71S83EU
alectinib
LIJ4CT1Z3Y
Antineoplastic Agents
0
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Lactams, Macrocyclic
0
Protein-Tyrosine Kinases
EC 2.7.10.1
Protein Kinase Inhibitors
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2560-2568Subventions
Organisme : Pfizer
Informations de copyright
© 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Int J Clin Oncol. 2019 Jul;24(7):731-770
pubmed: 31049758
Respir Med Case Rep. 2021 Jun 01;33:101440
pubmed: 34401280
Cancer Sci. 2019 Apr;110(4):1401-1407
pubmed: 30776174
Cancer Sci. 2020 May;111(5):1685-1691
pubmed: 32103551
Ann Oncol. 2019 Feb 1;30(2):171-210
pubmed: 30596843
J Thorac Oncol. 2020 Feb;15(2):258-265
pubmed: 31669591
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Lancet Oncol. 2017 Dec;18(12):1590-1599
pubmed: 29074098
Nature. 2007 Aug 2;448(7153):561-6
pubmed: 17625570
Cancer Discov. 2016 Oct;6(10):1118-1133
pubmed: 27432227
Cancer Cell. 2015 Jul 13;28(1):70-81
pubmed: 26144315
J Thorac Oncol. 2016 Feb;11(2):256-60
pubmed: 26845119
N Engl J Med. 2010 Oct 28;363(18):1693-703
pubmed: 20979469
Adv Ther. 2020 Jul;37(7):3311-3323
pubmed: 32472430
Ann Oncol. 2021 May;32(5):620-630
pubmed: 33639216
Lung Cancer (Auckl). 2017 Oct 24;8:191-206
pubmed: 29123433
Cancer Sci. 2023 Jun;114(6):2560-2568
pubmed: 36866958
Br J Clin Pharmacol. 2000 Nov;50(5):419-25
pubmed: 11069436
Future Oncol. 2022 Jun;18(17):2101-2111
pubmed: 35306859
J Thorac Oncol. 2009 Dec;4(12):1450-4
pubmed: 20009909
Cancer Sci. 2020 Oct;111(10):3726-3738
pubmed: 32681682
Lancet. 2017 Jul 1;390(10089):29-39
pubmed: 28501140
Drugs Real World Outcomes. 2020 Dec;7(4):261-269
pubmed: 32725539
Lancet Oncol. 2018 Dec;19(12):1654-1667
pubmed: 30413378
Pharmaceuticals (Basel). 2020 Nov 07;13(11):
pubmed: 33171712
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326